(Q33383954)

26 July 2017

1 reference

title

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia (English)

1 reference

26 July 2017

main subject

chronic myeloid leukemia

0 references

dasatinib monohydrate

1 reference

1 reference

Timothy Tyler

1

1 reference

26 July 2017

language of work or name

English

0 references

publication date

31 March 2009

1 reference

Annals of Pharmacotherapy

26 July 2017

published in

1 reference

26 July 2017

volume

43

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

920-927

1 reference

Chronic myeloid leukemia. Introduction

26 July 2017

cites work

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

21 January 2018

1 reference

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L570

1 reference

26 July 2017

1 reference